BioTransplant (BT) acquired Eligix, a developer of therapy for patients receiving bone marrow (or stem cell) transplants and related procedures to treat leukemia, lymphoma, and other diseases,
Missing: BioTransplant's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: BioTransplant's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing BioTransplant
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BioTransplant is included in 1 Expert Collection, including Regenerative Medicine.
Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).
BioTransplant Frequently Asked Questions (FAQ)
Where is BioTransplant's headquarters?
BioTransplant's headquarters is located at 101 Washington Street Suite 101 Foxborough, MA 02035, Foxborough.
What is BioTransplant's latest funding round?
BioTransplant's latest funding round is Series D.
How much did BioTransplant raise?
BioTransplant raised a total of $2.36M.
Who are the investors of BioTransplant?
Investors of BioTransplant include Rho Ventures.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.